Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Current Leases (2019 - 2024)

Whitehawk Therapeutics (WHWK) has disclosed Current Leases for 6 consecutive years, with $268000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Current Leases fell 38.25% to $268000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $268000.0, a 38.25% decrease, with the full-year FY2024 number at $268000.0, down 38.25% from a year prior.
  • Current Leases was $268000.0 for Q4 2024 at Whitehawk Therapeutics, down from $322000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $434000.0 in Q4 2023 to a low of $9955.0 in Q2 2021.
  • A 5-year average of $257931.6 and a median of $322000.0 in 2024 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: crashed 91.04% in 2021, then soared 3154.65% in 2022.
  • Whitehawk Therapeutics' Current Leases stood at $94787.0 in 2020, then soared by 38.2% to $131000.0 in 2021, then soared by 200.76% to $394000.0 in 2022, then rose by 10.15% to $434000.0 in 2023, then plummeted by 38.25% to $268000.0 in 2024.
  • Per Business Quant, the three most recent readings for WHWK's Current Leases are $268000.0 (Q4 2024), $322000.0 (Q3 2024), and $374000.0 (Q2 2024).